Bones are naturally more vulnerable to developing infections after sugery. The rate of surgical site infections in orthopaedic procedures ranges from 1.5% for total knee implantation to 6.8% for femural head replacement. Collatamp G can decrease this rate more than 50%.3
Studies show that using gentamicin-containing collagen implants such as Collatamp G in concurrence with standard antibiotic regimens significantly decreases the rate of surgical site infections in orthopaedic patients. As a result, patients who were given Collatamp G see a decrease in the number of rejected implants, likelihood of repeat surgery, length of hospital stays, and risk of death. In over 20 years of use and two million patients, no adverse events related to the use of Collatamp G have been reported.
Collatamp G has been studied in a variety of orthpaedic surgery types, including septic arthritis, arthoplasty, osteomyelitis, orthopaedic oncology, septic prosthesis loosening, lumbar discectomy, and open fractures. One to five Collatamp G impacts are placed adjacent to bone during surgery. Because Collatamp G is placed into the wound, it delivers a high dose of powerful antibiotic directly at the site of infection risk. Then the collagen breaks down and is easily resorbed by the body, avoiding the risk of systemic toxicity and associated side effects.
Collatamp G can also be placed into infected bone after debridement to treat infections after they occur.